Effect of magnet implant on iron biodistribution of Fe@C nanoparticles in the mouse

In vivo proinflammatory activity of generations 0-3 (G0-G3) polyamidoamine (PAMAM) nanoparticles

OBJECTIVE AND DESIGN

The aim of this study was to determine whether different generations (G) polyamidoamine (PAMAM) dendrimers possess proinflammatory activities in vivo.

MATERIAL OR SUBJECTS

Several hundred female CD-1 mice were used to test four different PAMAM dendrimers using the murine air pouch model.

TREATMENT

Mice received appropriate negative and positive controls or G0-G3 PAMAM nanoparticles at 100 and 500 µg/ml into air pouches.

METHODS

Exudates were harvested after 3, 6, 24 and 48 h. Cell pellets and supernatants were used to determine the number of total leukocytes and neutrophils and to detect the production of several analytes by an antibody array approach, respectively. One-way analysis of variance was used for statistical analysis.

RESULTS

PAMAM dendrimers rapidly increased a leukocyte influx after 3 h, the vast majority of cells being neutrophils. This was also observed after 6 and 24 h, and resolution of inflammation was noted after 48 h. In general, the increased production of a greater number of analytes detected in the exudates after 6 h correlated with the number of dendrimer generations (G3 > G2 > G1 > G0).

CONCLUSIONS

PAMAM dendrimers devoid of any delivering molecules possess proinflammatory activities in vivo by themselves, probably via the production of different chemokines released by air pouch lining cells.

Magnetic nanotherapeutics for dysregulated synaptic plasticity during neuroAIDS and drug abuse

The human immunodeficiency virus (HIV) is a neurotropic virus. It induces neurotoxicity and subsequent brain pathologies in different brain cells. Addiction to recreational drugs remarkably affects the initiation of HIV infections and expedites the progression of acquired immunodeficiency syndrome (AIDS) associated neuropathogenesis. Symptoms of HIV-associated neurocognitive disorders (HAND) are noticed in many AIDS patients. At least 50 % of HIV diagnosed cases show one or other kind of neuropathological signs or symptoms during different stages of disease progression. In the same line, mild to severe neurological alterations are seen in at least 80 % autopsies of AIDS patients. Neurological illnesses weaken the connections between neurons causing significant altercations in synaptic plasticity. Synaptic plasticity alterations during HIV infection and recreational drug abuse are mediated by complex cellular phenomena involving changes in gene expression and subsequent loss of dendritic and spine morphology and physiology. New treatment strategies with ability to deliver drugs across blood-brain barrier (BBB) are being intensively investigated. In this context, magnetic nanoparticles (MNPs) based nanoformulations have shown significant potential for target specificity, drug delivery, drug release, and bioavailability of desired amount of drugs in non-invasive brain targeting. MNPs-based potential therapies to promote neuronal plasticity during HIV infection and recreational drug abuse are being developed.

Toward improved selectivity of targeted delivery: the potential of magnetic nanoparticles

Magnetic nanoparticles, mostly iron oxide-based nanoparticles, have long been used as contrasting agents in magnetic resonance imaging (MRI) applications, heat mediators in hyperthermia treatments and carriers for targeted drug delivery. Magnetic nanoparticles offer some attractive characteristics for targeted drug delivery such as drug carrying ability, nano-scale dimensions and magnetism-driven selective targeting. In this issue, Escribano et al. demonstrated that iron oxide-based magnetic nanoparticles with an implanted magnet can improve selective targeting to the site of inflammation. This result opens a promising avenue for magnetic drug targeting to inflammatory diseases.